What this is
- How it works
- How it works isn't classified yet
- Tested for
- Parkinson Disease
- Main trialPhase 3
- “This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.”In the company’s words, NCT06553027 on ClinicalTrials.gov
Other drugs for Parkinson Disease
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibEisai · Merck & Co. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2026 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | |
| Phase 2Completed | 6 Nov 2021 | Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations | |
| Phase 2Completed | 30 Jan 2025 | Early Parkinson's Disease Monotherapy With CVN424 | |
| Phase 1Completed | 11 Nov 2022 | Relative Bioavailability and Food Effect Study of CVN424 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026